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Abstract: Ischemic stroke is a major cause of death and morbidity worldwide. It has been suggested
that polyunsaturated fatty acids (PUFAs) may be associated with a lower risk ischemic stroke, but this
has been far less studied than their role for coronary heart disease. In this paper, we summarize
the main findings from previous follow-up studies investigating associations between intake or
biomarkers of the major PUFAs including alpha-linolenic acid (ALA), marine n-3 PUFAs and linoleic
acid (LA) and the development of ischemic stroke. Several follow-up studies have suggested that
marine n-3 PUFAs may be associated with a lower risk of ischemic stroke although results have not
been consistent and limited knowledge exist on the individual marine n-3 PUFAs and ischemic stroke
and its subtypes. The role of ALA is less clear, but most studies have not supported that ALA is
appreciably associated with ischemic stroke risk. Some studies have supported that LA might be
associated with a lower risk of total ischemic stroke, while limited evidence exist on PUFAs and
ischemic stroke subtypes. The associations may depend on the macronutrients that PUFAs replace
and this substitution aspect together with focus on dietary patterns represent interesting areas for
future research.
Keywords: polyunsaturated fatty acids; ischemic stroke; observational prospective
studies; biomarkers
1. Introduction
Ischemic stroke is characterized by an episode of neurological dysfunction attributed to cerebral
infarction in the perfusion territory of an stenosed or occluded artery [1]. Ischemic stroke is a major
cause of death and disability worldwide, but some studies have indicated that adherence to a healthy
diet and lifestyle may be of importance for reduction of ischemic stroke risk [2,3].
An important part of a healthy diet is believed to be an increased intake of polyunsaturated fatty
acids (PUFAs). PUFAs are organic acids that naturally contains two or more double bonds in their
carbon chain and are named according to the number, configuration and position of these double
bonds [4]. PUFAs are upon ingestion incorporated into cell membranes and storage pools, utilised in
energy production or converted into longer and more unsaturated fatty acids, which may give rise to
biological compounds that may affect a variety of biological processes [5]. PUFAs have traditionally
been divided into n-3 PUFAs and n-6 PUFAs and these two families each consist of fatty acids with
varying carbon chain length and degree of unsaturation, which are important for their physiological
and biological properties [4]. The major n-3 PUFAs include the short-chain plant-derived n-3 PUFA,
alpha-linolenic acid (ALA, 18:3n-3), and the longer-chain marine n-3 PUFAs eicosapentaenoic acid
(EPA, 20:5n-3), docosapentaenoic acid (DPA, 22:5n-3) and docosahexaenoic acid (DHA, 22:6n-3).
The major dietary n-6 PUFA is linoleic acid (LA, 18:2n-6) and together with ALA are the PUFAs
consumed in largest amounts. The typical intake of LA in Western populations range between 10 to
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17 g/d, while the average intake of ALA varies between 0.5 to 2.3 g/d [5–7]. The major sources of LA
include plant oils, meat and eggs [6], while ALA is found in large amounts in some plant oils, but can
be also be found in walnuts, green vegetables, whole-grain cereals, margarines, dairy products and
meat [8–10]. LA and ALA are precursors for further desaturation and elongation products along a
shared metabolic pathway. LA can thus be converted into arachidonic acid (AA, 20:4n-6), while ALA
can be converted into LC n-3 PUFAs, however, the conversion efficiency seems to be limited in humans
and influenced by gender, genetics and intake of other fatty acids [5,11]. The LC n-3 PUFAs can be
acquired from seafood and especially fatty fish and their biological effects has been extensively studied
over the recent decades since Dyerberg and colleagues hypothesized that LC n-3 PUFAs in particular
EPA were protective against atherothrombosis [12–14].
LC n-3 PUFAs has been ascribed several effects that might be beneficial in the prevention
of ischemic stroke including lowering of triglycerides, inflammation, blood pressure and platelet
aggregability, and improved endothelial function and atherosclerotic plaque stability, which likely
are mediated by a combination of mechanisms [4,14–17]. On the other hand the biological effects of
other PUFAs have been less studied, but few studies have suggested that ALA might be associated
with anti-inflammatory and anti-atherosclerotic properties [18]. Whether these suggested effects is
mediated by ALA per se or can be attributed to its role as a precursor for LC n-3 PUFAs, however,
remains unclear. LA has been reported to be associated with lowering of low-density lipoprotein (LDL)
cholesterol, blood pressure and insulin resistance [19], all important for atherosclerotic risk. Concerns
have, however, been raised that LA could confer a higher risk of vascular disease due to its role as
a precursor of AA that gives rise to eicosanoids considered pro-inflammatory and pro-thrombotic
including formation of proinflammatory leukotriene B4 from leukocytes and proaggregatory and
vasoconstrictive thromboxane A2 [4]. However, stable isotope studies and clinical trials have indicated
that high intakes of LA do not seem to significantly increase tissue levels of AA or increased production
of inflammatory mediators [20]. Indeed, there is actually some indications that LA might possess
anti-inflammatory effects [20,21].
Several studies have suggested that LC n-3 PUFAs and LA may be associated with a lower
risk of coronary heart disease (CHD) [4,22–24]. Although, CHD and ischemic stroke may share
pathophysiological similarities, less is known about the role of PUFAs in relation to risk of ischemic
stroke and previous studies have not yielded consistent results.
The objective of this paper was to summarize the main findings from previous follow-up studies
investigating associations between intake or biomarkers of exposure of the major PUFAs (ALA, LC n-3
PUFAs, and LA) and ischemic stroke.
2. ALA and Ischemic Stroke
Few studies have investigated the association between ALA intake and ischemic stroke [25–29]
(Table 1). In the Monitoring Project on Risk Factors for Chronic Diseases Study (MORGEN Study),
dietary intake of ALA was inversely associated with the rate of total ischemic stroke among Dutch
men and women [25]. In the Cardiovascular Health Study (CHS), indications of a lower rate of total
ischemic stroke were observed when comparing the highest quintile of ALA intake with the lowest,
but no consistent pattern of association was observed across quintiles of ALA in this cohort of US
men and women [26]. Further, no clear association was observed between ALA intake and the rate
of total ischemic stroke among women enrolled into the Women’s Health Study [27] or the Swedish
Mammography Cohort [28] and among men and women enrolled into the Diet, Cancer and Health
(DCH) cohort [29]. Limited knowledge is available regarding the associations between ALA intake and
the risk of ischemic stroke subtypes but no appreciable pattern of associations were observed between
intake of ALA and the rate of ischemic stroke subtypes caused by large artery atherosclerosis, small
vessel-occlusion or cardioembolism in the DCH cohort [29] (Table 2).
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Table 1. Characteristics of observational follow-up studies investigating intake of alpha-linolenic acid (ALA) and total ischemic stroke.
Author and
Study
Study Population
and Country Sex
No. of
Participants
Baseline
Age (yrs)
Exposure
Assessment Intake (g/d)
No. of
Cases
Follow-up
(yrs)
Hazard Ratios
(95% CI) Variables Controlled for
De Goede et
al. 2011 [25]
The MORGEN
Study cohort; The
Netherlands
M+W 19,896 20–65 FFQ
Q1: 1.0
Q3: 1.3
Q5: 1.9
144 10.5
Q2: 0.63 (0.39; 1.02)
Q3: 0.45 (0.26; 0.77)
Q4: 0.55 (0.33; 0.92)
Q5: 0.70 (0.43; 1.12)
Age; sex; BMI; total energy intake;
cigarette smoking; educational
level; parental history of MI;
alcohol.
Larsson et al.
2012 [28]
The Swedish
Mammography
Cohort; Sweden
W 34,670 49–83 FFQ
Q1: 0.9
Q3: 1.1
Q5: 1.5
1310 10.4
Q2: 0.99 (0.83; 1.17)
Q3: 1.03 (0.86; 1.22)
Q4: 1.00 (0.84; 1.19)
Q5: 1.11 (0.93; 1.32)
Age; smoking status and
pack-years of smoking; education;
BMI; physical activity;
hypertension; diabetes; aspirin;
family history of MI; intakes of
alcohol, protein, fiber and
cholesterol.
Fretts et al.
2014 [26]
The CHS cohort;
United States M+W 2583 ≥65 FFQ
Q1: 1.3% 1
Q3: 1.8% 1
Q5: 2.4% 1
278 9.6 2
Q2: 0.89 (0.61; 1.30)
Q3: 0.84 (0.58; 1.22)
Q4: 1.08 (0.75; 1.54)
Q5: 0.70 (0.47; 1.04)
Age; sex; total energy intake; race;
enrollment site; education;
smoking status; diabetes; BMI;
waist circumference; physical
activity; alcohol; treated
hypertension.
Rhee et al.
2017 [27]
The WHS cohort;
United States W 38,392 ≥45 FFQ
Q1: 0.7% 3
Q3: 1.0% 3
Q5: 1.4% 3
807 18.2 2
Q2: 0.89 (0.71; 1.13)
Q3: 0.89 (0.71; 1.12)
Q4: 1.05 (0.84; 1.30)
Q5: 1.02 (0.82; 1.27)
Age; randomized treatment
assignment; BMI; smoking; alcohol;
physical activity; oral
contraceptive use; HRT;
multivitamins; total energy intake;
family history of MI; hypertension;
high cholesterol; diabetes.
Bork et al.
2018 [29]
The DCH cohort;
Denmark M+W 55,018 50–65 FFQ
Q1: 1.2
Q3: 1.8
Q5: 2.6
1859 13.5
Q2: 1.03 (0.87; 1.21)
Q3: 1.12 (0.95; 1.31)
Q4: 1.03 (0.87; 1.22)
Q5: 1.10 (0.93; 1.31)
Age; gender; length of schooling;
smoking; physical activity; waist
circumference adjusted for BMI;
alcohol.
Abbreviations: MORGEN, The Monitoring Project on Risk Factors for Chronic Diseases Study; M, men; W, Women; FFQ, Food Frequency Questionnaire; Q, Quintile; CI, Confidence
interval; BMI, Body mass index; MI, Myocardial infarction; CHS, Cardiovascular Health Study; WHS, Women’s Health Study; HRT, Hormone replacement therapy; DCH, Diet, Cancer and
Health. The presented measures of association was selected for models that included adjustment for lifestyle factors without including dietary covariates whenever possible. The lowest
quintile of intake was used as reference. 1 Percentage of total fatty acids; 2 Follow-up time was calculated as person-years of follow-up divided by the total number of participants; 3
Percentage of total energy intake.
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Table 2. Measures of association obtained in observational follow-up and nested case-control studies
investigating intake or biomarkers of major PUFAs in relation to ischemic stroke subtypes.
Author and Exposures of
Interest
Large Artery Occlusive
Infarctions
Small-Vessel and Lacunar
Infarctions Cardio-Embolic Infarctions
Iso et al. 2001 [30]
No. cases 88 142
EPA+DHA intake
HR Q2-5 vs. Q1:
Q2: 0.56 (0.28; 1.10)
Q3: 0.50 (0.25; 1.02)
Q4: 0.96 (0.51; 1.81)
Q5: 1.09 (0.52; 2.29)
HR Q2-5 vs. Q1:
Q2: 0.89 (0.55; 1.43)
Q3: 0.59 (0.34; 1.00)
Q4: 0.67 (0.39; 1.14)
Q5: 0.37 (0.19; 0.73)
Iso et al. 2002 [31]
No. of cases 19 95 8
ALA in serum OR: 0.82 (NS, CI not re-ported)per 1 SD increase 1
OR: 0.82 (NS, CI not re-ported)
per 1 SD increase 1
OR: 0.89 (NS, CI not re-ported)
per 1 SD increase 1
EPA in serum OR: 2.28 (1.14; 4.57) per 1 SDincrease 1
OR: 0.89 (NS, CI not re-ported)
per 1 SD increase 1
OR: 0.63 (NS, CI not re-ported)
per 1 SD increase 1
DPA in serum OR: 1.35 (NS, CI not re-ported)per 1 SD increase 1
OR: 1.17 (NS, CI not re-ported)
per 1 SD increase 1
OR: 1.59 (NS, CI not re-ported)
per 1 SD increase 1
DHA in serum OR: 1.53 (NS, CI not re-ported)per 1 SD increase 1
OR: 1.02 (NS, CI not re-ported)
per 1 SD increase 1
OR: 1.06 (NS, CI not re-ported)
per 1 SD increase 1
LA in serum OR: 0.66 (NS, CI not re-ported)per 1 SD increase 1
OR: 0.63 (0.46; 0.88) per 1 SD
increase
OR: 0.92 (NS, CI not re-ported)
per 1 SD increase 1
Yaemsiri et al. 2013 [32]
No. of cases 96 250 209
EPA in serum OR: 0.51 (0.23; 1.14) per 1 SDincrease 2
OR: 0.58 (0.36; 0.94) per 1 SD
increase 2
OR: 0.84 (0.55; 1.30) per 1 SD
increase 2
DPA in serum OR: 0.83 (0.47; 1.47) per 1 SDincrease 2
OR: 0.64 (0.44; 0.94) per 1 SD
increase 2
OR: 0.82 (0.55; 1.24) per 1 SD
increase 2
DHA in serum OR: 0.70 (0.36; 1.36) per 1 SDincrease 2
OR: 0.61 (0.40; 0.93) per 1 SD
increase 2
OR: 0.66 (0.43; 1.02) per 1 SD
increase 2
Bork et al. 2018 [29]
No. of cases 316 835 102
ALA intake
HR Q2-5 vs. Q1:
Q2: 1.03 (0.71; 1.51)
Q3: 0.91 (0.62; 1.34)
Q4: 0.90 (0.61; 1.34)
Q5: 0.96 (0.65; 1.44)
HR Q2-5 vs. Q1:
Q2: 1.08 (0.84; 1.39)
Q3: 1.23 (0.97; 1.56)
Q4: 1.09 (0.84; 1.40)
Q5: 1.25 (0.98; 1.61)
HR Q2-5 vs. Q1:
Q2: 1.30 (0.62; 2.72)
Q3: 1.23 (0.59; 2.56)
Q4: 1.08 (0.51; 2.29)
Q5: 1.31 (0.63; 2.76)
Bork et al. 2018 [33]
No. of cases 297 772 99
ALA in adipose tissue
HR Q2-5 vs. Q1:
Q2: 0.72 (0.48; 1.08)
Q3: 0.63 (0.41; 0.96)
Q4: 0.83 (0.56; 1.22)
Q5: 0.95 (0.65; 1.40)
HR Q2-5 vs. Q1:
Q2: 1.00 (0.77; 1.31)
Q3: 0.96 (0.73; 1.25)
Q4: 1.02 (0.78; 1.33)
Q5: 1.05 (0.80; 1.38)
HR Q2-5 vs. Q1:
Q2: 1.05 (0.53; 2.06)
Q3: 1.16 (0.59; 2.27)
Q4: 0.90 (0.43; 1.87)
Q5: 1.91 (0.98; 3.70)
Saber et al. 2017 [34]
No. of cases 408 256
EPA in PL
HR Q2-4 vs. Q1:
Q2: 1.03 (0.70; 1.52)
Q3: 0.97 (0.65; 1.44)
Q4: 1.06 (0.71; 1.59)
HR Q2-4 vs. Q1:
Q2: 1.10 (0.72; 1.66)
Q3: 0.96 (0.62; 1.50)
Q4: 0.94 (0.61; 1.45)
DPA in PL
HR for Q2-4 vs. Q1:
Q2: 1.05 (0.72; 1.53)
Q3: 1.02 (0.69; 1.53)
Q4: 0.98 (0.64; 1.53)
HR Q2-4 vs. Q1:
Q2: 0.75 (0.50; 1.14)
Q3: 0.83 (0.55; 1.35)
Q4: 0.59 (0.38; 0.93)
DHA in PL
HR Q2-4 vs. Q1:
Q2: 0.88 (0.60; 1.16)
Q3: 0.72 (0.48; 1.07)
Q4: 0.53 (0.34; 0.83)
HR Q2-4 vs. Q1:
Q2: 1.25 (0.83; 1.90)
Q3: 1.07 (0.69; 1.65)
Q4: 1.09 (0.69; 1.72)
Venø et al. 2019 [35]
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Table 2. Cont.
Author and Exposures of
Interest
Large Artery Occlusive
Infarctions
Small-Vessel and Lacunar
Infarctions Cardio-Embolic Infarctions
No. of cases in dietary
analyses 319 844 102
No. of cases in AT analyses 300 781 99
Total LC n-3 intake
HR Q2-4 vs. Q1:
Q2: 0.97 (0.72; 1.30)
Q3: 0.88 (0.65; 1.19)
Q4: 0.69 (0.50; 0.95)
HR Q2-4 vs. Q1:
Q2: 1.15 (0.94; 1.40)
Q3: 1.20 (0.98; 1.45)
Q4: 1.06 (0.87: 1.30)
HR Q2-4 vs. Q1:
Q2: 1.36 (0.69; 2.66)
Q3: 1.49 (0.78; 2.88)
Q4: 2.50 (1.38; 4.53)
Total LC n-3 in AT
HR Q2-4 vs. Q1:
Q2: 0.86 (0.61; 1.22)
Q3: 1.09 (0.78; 1.52)
Q4: 0.78 (0.53; 1.13)
HR Q2-4 vs. Q1:
Q2: 0.91 (0.72; 1.15)
Q3: 1.05 (0.83; 1.32)
Q4: 0.99 (0.79; 1.26)
HR Q2-4 vs. Q1:
Q2: 2.08 (1.04; 4.15)
Q3: 2.04 (1.03; 4.04)
Q4: 2.63 (1.33; 5.19)
EPA intake
HR Q2-4 vs. Q1:
Q2: 0.86 (0.64; 1.16)
Q3: 0.82 (0.60; 1.11)
Q4: 0.66 (0.48; 0.91)
HR Q2-4 vs. Q1:
Q2: 1.14 (0.94; 1.38)
Q3: 1.16 (0.96; 1.41)
Q4: 1.05 (0.86; 1.28)
HR Q2-4 vs. Q1:
Q2: 1.17 (0.58; 2.35)
Q3: 2.34 (1.27; 4.30)
Q4: 2.02 (1.09; 3.73)
EPA in AT
HR Q2-4 vs. Q1:
Q2: 0.96 (0.70; 1.32)
Q3: 0.64 (0.43; 0.94)
Q4: 0.52 (0.36; 0.76)
HR Q2-4 vs. Q1:
Q2: 0.84 (0.68; 1.04)
Q3: 0.61 (0.47; 0.79)
Q4: 0.69 (0.55; 0.88)
HR Q2-4 vs. Q1:
Q2: 1.13 (0.61; 2.11)
Q3: 1.06 (0.52; 2.14)
Q4: 1.52 (0.82; 2.81)
DPA intake
HR Q2-4 vs. Q1:
Q2: 1.01 (0.74; 1.38)
Q3: 0.91 (0.67; 1.25)
Q4: 0.88 (0.64; 1.21)
HR Q2-4 vs. Q1:
Q2: 1.27 (1.04; 1.55)
Q3: 1.21 (0.99; 1.48)
Q4: 1.19 (0.98; 1.46)
HR Q2-4 vs. Q1:
Q2: 0.80 (0.41: 1.56)
Q3: 1.14 (0.63; 2.08)
Q4: 1.68 (0.96; 2.91)
DPA in AT
HR Q2-4 vs. Q1:
Q2: 1.46 (1.04; 2.07)
Q3: 1.23 (0.86; 1.76)
Q4: 1.02 (0.69; 1.51)
HR Q2-4 vs. Q1:
Q2: 1.37 (1.08; 1.74)
Q3: 1.29 (1.01; 1.64)
Q4: 1.19 (0.93; 1.52)
HR Q2-4 vs. Q1:
Q2: 2.45 (1.19; 5.05)
Q3: 2.61 (1.30; 5.25)
Q4: 3.06 (1.50; 6.24)
DHA intake
HR Q2-4 vs. Q1:
Q2: 0.90 (0.67; 1.22)
Q3: 0.86 (0.63; 1.16)
Q4: 0.72 (0.53; 0.99)
HR Q2-4 vs. Q1:
Q2: 1.26 (1.04; 1.54)
Q3: 1.17 (0.96; 1.43)
Q4: 1.13 (0.93; 1.38)
HR Q2-4 vs. Q1:
Q2: 0.97 (0.50; 1.89)
Q3: 1.27 (0.68; 2.36)
Q4: 2.12 (1.21; 3.69)
DHA in AT
HR Q2-4 vs. Q1:
Q2: 0.94 (0.67; 1.32)
Q3: 1.08 (0.77; 1.52)
Q4: 0.79 (0.54; 1.16)
HR Q2-4 vs. Q1:
Q2: 0.86 (0.68; 1.09)
Q3: 1.07 (0.85; 1.34)
Q4: 0.92 (0.72; 1.17)
HR Q2-4 vs. Q1:
Q2: 1.37 (0.71; 2.64)
Q3: 1.64 (0.87; 3.10)
Q4: 2.00 (1.04; 3.84)
Venø et al. 2017 [36]
No. of cases 319 844 102
LA intake
LA for SFA:
HR: 0.84 (0.57; 1.25)
LA for MUFA:
HR: 1.05 (0.58; 1.90)
LA for glycemic
carbohydrates:
HR: 0.96 (0.64; 1.44)
LA for SFA:
HR: 0.96 (0.75; 1.23)
LA for MUFA:
HR: 0.67 (0.46; 0.96)
LA for glycemic
carbohydrates:
HR: 0.82 (0.64; 1.05)
LA for SFA:
HR: 1.46 (0.75; 2.85)
LA for MUFA:
HR: 1.35 (0.51; 3.55)
LA for glycemic
carbohydrates:
HR: 1.55 (0.81; 3.00)
Venø et al. 2018 [37]
No. of cases 300 781 99
LA in AT
HR Q2-4 vs. Q1:
Q2: 0.72 (0.51; 1.01)
Q3: 0.84 (0.61; 1.17)
Q4: 0.61 (0.43; 0.88)
HR Q2-4 vs. Q1:
Q2: 0.90 (0.72; 1.13)
Q3: 0.87 (0.69; 1.03)
Q4: 0.87 (0.69; 1.11)
HR Q2-4 vs. Q1:
Q2: 1.28 (0.75; 2.19)
Q3: 0.71 (0.37; 1.37)
Q4: 0.86 (0.46; 1.59)
Abbreviations: NS, Not statistically significant; AT, Adipose tissue. 1 Univariate analysis. 2 99% Confidence interval.
The presented measures of association was selected for models that included adjustment for lifestyle factors without
including dietary covariates whenever possible. See Table 1 and Tables 3–7 for study characteristics.
The findings from previous follow-up and nested-case control studies using biomarkers of ALA
to investigate associations with ischemic stroke have not been conclusive [26,31–33,38–40] (Table 3).
In a large case-cohort study based on data from the DCH cohort we reported indications of a U-shaped
pattern of association between adipose tissue content of ALA and the rate of total ischemic stroke
although not statistically significant [33]. A follow-up study based on the Finish Kuopio Ischaemic
Heart Disease Risk Factors (KIHD) study also reported indications of a U-shaped pattern of association
between quartiles of ALA content in serum and total ischemic stroke, while a nested case-control
study reported a modest non-significant inverse association between ALA in serum and total ischemic
stroke [32,40]. In contrast, several other biomarker studies did not find ALA content in serum, plasma
phospholipids or cholesterol esters associated with the risk of total ischemic stroke [26,31,38,39].
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Table 3. Characteristics of observational follow-up and nested case-control studies investigating biomarkers of alpha-linolenic acid (ALA) and total ischemic stroke.
Author and
Study
Study Population,
Design and Country Sex
No. of Partici-Pants
and Cases
Baseline Age
(yrs) Biomarker
Concentrations
(%)
Follow-Up
(yrs)
Measure of
Association (95% CI) Variables Controlled for
Iso et al. 2002
[31]
A Japanese
cardiovascular risk
survey population;
Nested case-control;
Japan
M+W 122 cases & 366controls 40–85 ALA in serum
Cases: 1.0%
Controls: 1.0% Not reported
OR: 0.86 (NS, CI not
reported) per 1 SD
increase in ALA
Univariate analysis. Matched by
age; sex; community; year of
serum storage; fasting status.
De Goede et
al. 2013 [38]
The MORGEN Study
cohort; Nested-case
control; The
Netherlands
M+W 93 cases & 93 controls 20–65 ALA in CE Cases: 0.53%Controls: 0.52% 10.5
OR: 1.02 (0.71; 1.46) for
1 SD increase in ALA
Age; gender; enrollment date;
smoking; BMI; alcohol; high
educational level; diabetes;
hypertension;
hypercholesterolemia.
Yamagishi et
al. 2013 [39]
The Minneapolis field
center of the ARIC
cohort; Follow-up;
United States
M+W 3870 subjectsincluding 168 cases 45–65
ALA in PL
and CE,
separately
Mean:
CE: 0.4%
PL: 0.1%
19.9
HR for Q4 vs. Q1:
CE: 1.14 (0.76; 1.72)
PL: 1.29 (0.82; 2.02)
Age and sex. The authors stated
that the point estimated did not
materially change after
additional adjustment for
smoking status; cigarette-years
and alcohol intake.
Yaemsiri et al.
2013 [32]
The WHI-OS cohort;
Nested case-control;
United status
W 964 cases & 964controls 50–79 ALA in serum
Cases: 0.53%
Controls: 0.55% Not reported
OR: 0.90 (0.74; 1.08) for
1 SD increase in ALA 2
Age; race; time of follow-up;
BMI; smoking status; diabetes;
aspirin use.
Fretts et al.
2014 [26]
The CHS cohort;
Follow-up; United
States
M+W 2709 subjectsincluding 337 cases ≥65 ALA in PL
Q1: 0.09%
Q3: 0.14%
Q5: 0.22%
11.3 1
Q2: 0.92 (0.65; 1.30)
Q3: 1.01 (0.72; 1.43)
Q4: 0.84 (0.59; 1.20)
Q5: 0.97 (0.69; 1.36)
Age; sex; race; enrollment site;
education; smoking status;
diabetes; BMI; waist
circumference; physical activity;
alcohol; treated hypertension.
Daneshmand
et al. 2016 [40]
The KIHD cohort;
Follow-up; Finland M
1828 subjects
including 153 cases 42–60 ALA in serum
Q1: <0.58%
Q4: >0.87% 21.2
Q2: 0.89 (0.58; 1.36)
Q3: 0.63 (0.39; 1.02)
Q4: 0.90 (0.58; 1.41)
Age; examination year; BMI;
smoking status; physical activity;
alcohol.
Bork et al.
2018 [33]
The DCH cohort;
Case-cohort;
Denmark
M+W 54,648 subjectsincluding 1735 cases 50–65
ALA in
adipose tissue
Q1: 0.64%
Q3: 0.84%
Q5: 1.05%
13.4
Q2: 0.95 (0.78; 1.16)
Q3: 0.86 (0.70; 1.06)
Q4: 0.93 (0.76; 1.14)
Q5: 1.01 (0.82; 1.23)
Age; sex; duration of schooling;
smoking; physical activity; waist
circumference adjusted for BMI;
alcohol.
Abbreviations: M, men; W, Women; OR, odds ratio; CI, Confidence interval; NS, not statistically significant; SD, standard deviation; MORGEN, The Monitoring Project on Risk Factors for
Chronic Diseases; CE, Cholesterol ester; BMI, Body mass index; ARIC, Atherosclerosis Risk in Communities; PL, Plasma phospholipids; HR, Hazard ratio; Q, Quintile; CHS, Cardiovascular
Health Study; KIHD, The Kuopio, Ischaemic Heart Disease Risk Factor Study; WHI-OS, The Women’s Health Initiative Observational Follow-up Study; DCH, Diet, Cancer and Health.
The presented measures of association was selected for models that included adjustment for lifestyle factors without including dietary covariates whenever possible. The lowest
group of exposure was used as reference unless otherwise indicated. 1 Follow-up time was calculated as person-years of follow-up divided by the total number of participants; 2 99%
confidence interval.
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Limited data are available on biomarkers of ALA and ischemic stroke subtypes (Table 2). However,
data from the DCH cohort suggested a statistically significant U-shaped association between ALA
content in adipose tissue and the rate of ischemic stroke due to large artery atherosclerosis with the
lowest rate observed around the median content of ALA in adipose tissue [33]. In contrast, a positive
statistically non-significant association was observed between ALA content in adipose tissue and the
rate of ischemic stroke due to cardioembolism, whereas no appreciable association was found between
ALA in adipose tissue and ischemic stroke due to small-vessel occlusion [33].
In summary, previous studies evaluating either intake of ALA or content of ALA in blood
components or adipose tissue have shown conflicting results, but most studies does not support that
ALA exposure is inversely associated with ischemic stroke risk.
3. Marine LC n-3 PUFAs and Ischemic Stroke
Several studies have investigated the association between intake of LC n-3 PUFAs and total
ischemic stroke [27,28,30,35,41–46] (Table 4) and has recently been reviewed [47]. In brief, findings from
the Nurses’ Health Study (NHS) indicated a statistically non-significant inverse pattern of associations
between EPA+DHA intake and the rate of total ischemic stroke [30]. Analyses of ischemic stroke
subtypes showed an inverse pattern of associations between EPA+DHA intake and lacunar infarctions,
while no clear associations were observed for large artery occlusive infarctions [30] (Table 2). Lower
rates of total ischemic stroke across quintiles of EPA+DHA intake were observed in the Swedish
Mammography cohort [28] and in the Health Professionals Follow Study (HPFS) although results
were not statistically significant in the latter when comparing the highest quintile of intake with the
lowest [41]. In the MORGEN study, gender-specific analyses indicated lower rates of total ischemic
stroke in subjects with a high EPA+DHA intake, but the confidence intervals were wide and the point
estimates were not statistically significant [42]. A recent study from our groups by Venø et al. [35]
investigated associations between dietary intake of total marine LC n-3 PUFAs and of individual
marine n-3 PUFAs and the rate of total ischemic stroke and ischemic stroke subtypes using data from
the DCH cohort. In dietary analyses, no appreciable associations were observed between intake of
total and individual n-3 PUFAs, EPA or DHA and the rate of total ischemic stroke [35]. Also, in five
other follow-up studies, no consistent pattern of associations between EPA+DHA intake and rate of
total ischemic strokes were reported [27,43–46]. However, in the study by Venø et al. a high intake of
total n-3 PUFAs, EPA and DHA was statistically significantly associated with lower rates of ischemic
stroke due to large artery atherosclerosis when comparing the highest quartile of intake with the
lowest [35] (Table 2). In contrast, indications of higher rates of ischemic stroke due to cardioembolism
were observed with intake of LC n-3 PUFAs, whereas no consistent pattern of association was observed
between LC n-3 PUFAs and the rate of ischemic stroke due small-vessel occlusions [35] (Table 2).
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Table 4. Characteristics of observational follow-up studies investigating intake of LC n-3 PUFAs and total ischemic stroke.
Author and
Study
Study Population
Country Sex
No. of
Participants
Baseline
Age (yrs)
Exposure
Assessment Intake (mg/d)
No. of
Cases
Follow-up
(yrs)
Hazard Ratios
(95% CI) Variables Controlled for
Iso et al.
2001 [30]
The NHS cohort;
United States W 79,839 34–59 FFQ
EPA+DHA
Q1: 77
Q3: 171
Q5: 481
303 14
Q2: 0.83 (0.59; 1.18)
Q3: 0.67 (0.47; 0.98)
Q4: 0.82 (0.57; 1.18)
Q5: 0.71 (0.46; 1.10)
Age; smoking status; time interval; joules;
BMI; alcohol; menopausal status;
post-menopausal hormone use; vigorous
exercise; aspirin; multivitamins;
hypertension; fruit; vegetables; SFA; trans
unsaturated fat; linoleic acid; animal
protein; calcium.
He et al.
2002 [41]
The HPFS cohort;
United States M 43,671 40–75 FFQ
EPA+DHA
Q1: <50
Q3: 200–400
Q5: ≥600
377 12
Q2: 0.56 (0.35; 0.88)
Q3: 0.63 (0.40; 0.98)
Q4: 0.54 (0.32; 0.91)
Q5: 0.73 (0.43; 1.25)
Age; smoking status; BMI; physical
activity; hypertension; aspirin; fish oil;
multivitamins; total calories; total fat; SFA;
trans-unsaturated fat; alcohol; potassium;
magnesium; fruit; vegetables;
hypercholesterolemia.
Yamagishi et
al. 2008 [46]
The JACC cohort,
Japan M+W 57,972 40–79 FFQ
Total LCn-3
Q1: <1180
Q5: ≥2110
319 12.7
Q2: 1.06 (0.69; 1.63)
Q3: 1.31 (0.85; 2.01)
Q4: 1.07 (0.68; 1.69)
Q5: 1.17 (0.71; 1.92)
Age; sex; hypertension; diabetes; smoking
status; alcohol; BMI; mental stress;
walking; sports; education levels; total
energy; intake of cholesterol, SFA, n-6
PUFAs, vegetables; fruit.
Wallström et
al. 2011 [45]
The Malmö Diet
and Cancer cohort,
Sweden
M & W M: 8083W: 12,402 44–73
Combined
FFQ, 7-day
diet history
and 1 hour
diet
interview
EPA+DHA
M:
Q1: 0.08% 1
Q3: 0.19% 1
Q5: 0.53% 1
W:
Q1: 0.07% 1
Q3: 0.18% 1
Q5: 0.49% 1
M: 397
W: 346 13.5
M:
Q2: 1.36 (0.97; 1.89)
Q3: 1.29 (0.92; 1.80)
Q4: 1.12 (0.80; 1.57)
Q5: 1.12 (0.80; 1.57)
W:
Q2: 0.87 (0.60; 1.26)
Q3: 0.98 (0.68; 1.40)
Q4: 0.98 (0.69; 1.41)
Q5: 1.04 (0.73; 1.48)
Age; diet assessment method version; total
energy intake; season; BMI; smoking;
education; alcohol; systolic blood pressure,
anti-hypertensive treatment;
anti-hyperlipidemic treatment; leisure
time physical activity; dietary fiber.
Montonen et
al. 2009 [43]
The Finnish Mobile
Clinic Health
Examination Survey
cohort, Finland
M+W 3958 40–79
Dietary
history
interview
EPA+DHA
Q1: 102
Q4: 655
364 28
Q2: 0.95 (0.71; 1.28
Q3: 0.99 (0.74; 1.33)
Q4: 0.91 (0.66; 1.26)
Age; sex; energy intake; smoking; BMI;
physical activity; geographic area;
occupation; diabetes; post-hormonal
hormone use; hypertension; S-cholesterol;
intake of butter, vegetables, fruit and
berries.
Larsson et al.
2012 [28]
The Swedish
Mammography
cohort; Sweden
W 34,670 49–83 FFQ
EPA+DHA
Q1: 131
Q3: 289
Q5: 559
1310 10.4
Q2: 0.88 (0.74; 1.04)
Q3: 0.84 (0.70; 1.01)
Q4: 0.83 (0.69; 0.99)
Q5: 0.83 (0.69; 0.99)
Age; smoking status and pack-years of
smoking; education; BMI; physical
activity; hypertension; diabetes; aspirin;
family history of MI; intakes of alcohol,
protein, fiber and cholesterol.
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Table 4. Cont.
Author and
Study
Study Population
Country Sex
No. of
Participants
Baseline
Age (yrs)
Exposure
Assessment Intake (mg/d)
No. of
Cases
Follow-up
(yrs)
Hazard Ratios
(95% CI) Variables Controlled for
De Goede et
al. 2012 [42]
The MORGEN
Study cohort; The
Netherlands
M & W M: 8,988W:11,081 20–65 FFQ
EPA+DHA
M:
Q1: 44
Q4: 241
W:
Q1: 36
Q4: 225
M: 80
W: 64 10.5
M:
Q2: 0.93 (0.50; 1.74)
Q3: 0.87 (0.46; 1.65)
Q4: 0.85 (0.45; 1.60)
W:
Q2: 0.98 (0.50; 1.91)
Q3: 0.98 (0.50; 1.93)
Q4: 0.62 (0.29; 1.35)
Age; smoking; BMI; educational level;
parental history of MI; alcohol; total
energy intake; intake of fiber, vitamin C,
beta-carotene, SFAs, trans fatty acids,
MUFAs, linoleic acid and ALA.
Kippler et al.
2016 [44]
The Cohort of
Swedish Men,
Sweden
M 39,948 45–79 FFQ
EPA+DHA
Q1:180
Q4: 730
2286 12
Q2: 1.02 (0.90; 1.16)
Q3: 0.98 (0.85; 1.13)
Q4: 1.09 (0.94; 1.26)
Age; educational level; family history of
MI; high cholesterol; hypertension; atrial
fibrillation; aspirin; BMI; smoking status;
alcohol; physical activity; fish oil
supplements; energy intake; intake of fruit,
vegetables, red and processed meat, dairy
products, SFAs, MeHg and PCB.
Rhee et al.
2017 [27]
The WHS cohort;
United States W 38,392 ≥45 FFQ
EPA+DHA
Q1: 0.06% 1
Q3: 0.16% 1
Q5: 0.40% 1
807 18.2 2
Q2: 0.99 (0.80; 1.23)
Q3: 0.90 (0.72; 1.14)
Q4: 0.92 (0.74; 1.14)
Q5: 1.04 (0.84; 1.29)
Age; randomized treatment assignment;
BMI; smoking; alcohol; physical activity;
oral conceptive use; HRT; multivitamin
use; energy intake; family history of MI;
hypertension; high cholesterol; diabetes.
Venø et al.
2018 [35]
The DCH cohort;
Denmark M+W 55,338 50–65 FFQ
Total LCn-3
median: ~700 1879 13.5
Q2: 1.06 (0.93; 1.21)
Q3: 1.06 (0.93; 1.21)
Q4: 1.06 (0.93; 1.20)
Age; sex; education; waist circumference
adjusted by BMI; smoking; physical
activity; alcohol; alcohol abstain.
Abbreviations: NHS, Nurses’s Health Study; W, Women; FFQ, Food Frequency Questionnaire; EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid; Q, Quintile; CI, Confidence
interval; BMI, Body mass index; SFA, Saturated fatty acids; M, men; HPFS, Health Professionals Follow-up Study; JACC, Japan Collaborative Cohort Study for Evaluation of Cancer
Risk Study; LCn-3, Long-chain n-3 PUFAs; MI, Myocardial infarction; MORGEN, Monitoring Project on Risk Factors for Chronic Diseases; MUFA, Monounsaturated fatty acids; MeHg,
Methylmercery; PCB, Polychlorinated biphenyls; WHS, Women’s Health Study; DCH, Diet, Cancer and Health. The presented measures of association was selected for models that
included adjustment for lifestyle factors without including dietary covariates whenever possible. The lowest group of exposure was used as reference unless otherwise indicated. 1
Percentage of total energy intake; 2 Follow-up time was calculated as person years divided by the total number of participants.
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Some biomarker studies have investigated the associations between levels of LC n-3 PUFAs in
blood compartments or adipose tissue and the risk of ischemic stroke [31,32,34,35,38–40,48] (Table 5).
Thus, a the content of EPA, DPA and DHA in plasma phospholipids was analysed in relation to
ischemic stroke and its subtypes using pooled data from the CHS, NHS and HPFS [34]. Lower rates
of total ischemic stroke was observed when comparing the highest quintile of content of DPA and
DHA with the lowest, respectively, while no appreciable association was found for EPA [34]. However,
the associations seemed to depend on the ischemic stroke subtype in question (Table 2). In analyses
of ischemic stroke subtypes, DHA was associated with the rate of atherothrombotic strokes (large
artery and small-vessel infarctions), whereas no association was found for EPA and DPA. However,
DPA was associated with lower rates of cardioembolic strokes, whereas no associations were observed
between EPA or DHA and the rate of cardioembolic stroke [34]. Few other studies have supported
that circulating biomarkers of LC n-3 PUFAs might be associated with a lower risk of ischemic stroke
although results have not been consistent [31,32,38,40,48] (Table 5).
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Table 5. Characteristics of observational follow-up and nested case-control studies investigating biomarkers of LC n-3 PUFAs and total ischemic stroke.
Author and
Study
Study Population,
Design and Country Sex
No. of Partici-pants
and Cases
Baseline Age
(yrs) Biomarker
Concentrations
(%)
Follow-up
(yrs)
Measure of
Association (95% CI) Variables Controlled for
Iso et al. 2002
[31]
A Japanese
cardio-vascular risk
survey population;
Nested case-control;
Japan
M+W 122 cases & 366controls 40–85
EPA, DPA and
DHA in serum
(separately)
EPA:
Cases: 3.6
Controls: 3.7
DHA:
Cases: 4.5
Controls: 4.4
Not reported
OR: 1.01 (NS, CI not
reported) per 1 SD
increase in EPA OR:
1.03 (NS, CI not
reported) per 1 SD
increase in DHA
Univariate analysis. Matched by age;
sex; community; year of serum storage;
fasting status.
De Goede et
al. 2013 [38]
The MORGEN Study
cohort; Nested-case
control; The
Netherlands
M+W 93 cases & 93 controls 20–65 EPA+DHA inCE
Cases: 1.57
Controls: 1.25 10.5
OR: 1.33 (0.96; 1.84) for
1 SD increase in
EPA+DHA
Age; gender; enrollment date; smoking;
BMI; alcohol; high educational level;
diabetes; hypertension;
hypercholesterolemia.
Mozaffarian et
al. 2013 [48]
The CHS cohort;
Follow-up; United
States
M+W 2692 subjectsincluding 319 cases ≥65
Total LCn-3,
EPA, DPA and
DHA in PL
Total LCn-3
Q1: 3.17
Q3: 4.21
Q5: 6.04
11.5 1
Q2: 0.88 (0.63; 1.23)
Q3: 0.77 (0.54; 1.08)
Q4: 0.93 (0.66; 1.31)
Q5: 0.63 (0.43; 0.94)
Age; sex; race; enrollment site; fatty acid
measurement batch; education; smoking
status; diabetes; atrial fibrillation;
treated hypertension; leisure time
physical activity; BMI; waist
circumference; alcohol; intake of broiled
and baked fish, fried fish, red meat,
fruits, vegetables and fiber.
Yaemsiri et al.
2013 [32]
The WHI-OS cohort;
Nested case-control;
United status
W 964 cases & 964controls 50–79
EPA, DPA and
DHA in serum
(separately)
EPA:
Cases: 0.56
Controls: 0.60
DHA:
Cases: 1.75
Controls: 1.97
Not reported
OR: 0.84 (0.70; 1.01) for
1 SD increase in EPA 2
OR: 0.72 (0.59; 0.87) for
1 SD increase in DHA 2
Age; race; time of follow-up; BMI;
smoking status; diabetes; aspirin.
Yamagishi et
al. 2013 [39]
The Minneapolis field
center of the ARIC
cohort; Follow-up;
United States
M+W 3870 subjectsincluding 168 cases 45–65
Total LCn-3,
EPA and DHA
in PL and CE
(separately)
Total LCn-3
CE:
Q1: 0.22–0.77
Q4: 1.15–6.02
PL:
Q1: 1.51–3.57
Q4: 4.75–13.5
19.9
HR for Q4 vs. Q1:
CE: 1.16 (0.75; 1.79)
PL: 0.86 (0.56; 1.32)
Age and sex. The authors stated that the
point estimated did not materially
change after additional adjustment for
smoking status; cigarette-years and
alcohol intake.
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Table 5. Cont.
Author and
Study
Study Population,
Design and Country Sex
No. of Partici-pants
and Cases
Baseline Age
(yrs) Biomarker
Concentrations
(%)
Follow-up
(yrs)
Measure of
Association (95% CI) Variables Controlled for
Daneshmand
et al. 2016 [40]
The KIHD cohort;
Follow-up; Finland M
1828 subjects
including 153 cases 42–60
Total LCn-3,
EPA, DPA and
DHA in serum
Total LCn-3
Q1: <3.63%
Q4: >5.34%
21.2
Q2: 0.66 (0.41; 1.07)
Q3: 0.91 (0.58; 1.42)
Q4: 0.98 (0.64; 1.51)
Age; examination year; BMI; smoking
status; physical activity; alcohol.
Saber et al.
2017 [34]
Pooled analysis of the
NHS and HFPS
(nested case-control),
and the CHS
(follow-up) cohorts,
United States
M+W
A total of 953 cases
and 437 controls from
the NHS and HFPS
and 3941 subjects
from the CHS
NHS:
30–55
HFPS:
40–75
CHS:
≥65
EPA, DPA and
DHA in PL
(separately)
Cohort-specific fatty
acid content in
quartiles can be
found in the paper.
NHS+HPFS:
11.2
CHS: 8.3
EPA:
Q2: 0.95 (0.77; 1.18)
Q3: 0.93 (0.74; 1.16)
Q4: 0.94 (0.77; 1.19)
DHA:
Q2: 0.93 (0.75; 1.14)
Q3: 0.85 (0.71; 1.10)
Q4: 0.80 (0.63; 1.00)
Age; race; sex; smoking status; physical
activity; alcohol; hypertension; family
history of diabetes; parental history of
CVD; menopausal status;
postmenopausal hormone use; BMI;
aspirin; intake of processed and
unprocessed meat, fruits and vegetables.
Venø et al.
2019 [35]
The DCH cohort;
Case-cohort,
Denmark
M+W 55,338 subjectsincluding 1755 cases 50–65
Total LCn-3,
EPA, DPA and
DPA in
adipose tissue
Total LCn-3:
Q1: 0.42
Q4: 0.94
13.5
Q2: 0.98 (0.82; 1.17)
Q3: 1.12 (0.94; 1.33)
Q4: 1.08 (0.90; 1.30)
Age; sex; education; waist circumference
adjusted for BMI; smoking; physical
activity; alcohol and alcohol abstain.
Abbreviations: M, men; W, Women; EPA, Eicosapentaenoic acid; DPA, Docosapentaenoic acid; DHA, Docosahexaenoic acid; OR, Odds ratio; CI, Confidence interval; NS, Not statistically
significant; SD, Standard deviation; MORGEN, The Monitoring Project on Risk Factors for Chronic Diseases; CE, Cholesterol esters; BMI, Body mass index; CHS, Cardiovascular Health
Study; LC n-3, Long-chain n-3 PUFAs, PL, Plasma phospholipids; Q, Quintile; WHI-OS, Women’s Health Initiative Observational Follow-up Study; KIHD, The Kuopio, Ischaemic Heart
Disease Risk Factor Study; NHS, Nurses’ Health Study; HPFS, Health Professionals Follow-up Study; DCH, Diet, Cancer and Health. The presented measures of association was selected
for models that included adjustment for lifestyle factors without including dietary covariates whenever possible. The lowest group of exposure was used as reference unless otherwise
indicated. 1 Follow-up time was calculated as person years divided by the total number of participants; 2 99% confidence interval.
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The associations between adipose tissue content of LC n-3 PUFAs and the risk of ischemic
stroke and ischemic stroke subtypes were investigated based on data from the DCH cohort and no
appreciable association was observed between total adipose tissue of LC n-3 PUFAs and the rate
of total ischemic stroke [35]. However, the EPA content in adipose tissue was inversely associated
with the rate of total ischemic stroke when comparing the highest with the lowest quintile [35]. In
contrast, adipose tissue content of DPA seemed to be associated with a higher rate of total ischemic
stroke, whereas no association was found for DHA [35]. In analyses of ischemic stroke subtypes, the
content of EPA in adipose tissue was inversely associated with the rate of ischemic stroke due to
large artery atherosclerosis and small-vessel occlusions, while a higher rate of ischemic stroke due
to cardioembolism was noted when comparing the highest quartile with the lowest although not
statistically significant [35] (Table 2). Adipose tissue content of DPA and DHA was associated with
higher rates of ischemic stroke caused by cardioembolism whereas no consistent pattern of association
was found for ischemic stroke caused by large artery atherosclerosis or small-vessel occlusions [35]
(Table 2).
In summary, several large prospective studies evaluating EPA and/or DHA intake or their content
in blood components or adipose tissue have suggested an inverse association although results have
not been consistent. The associations between LC n-3 PUFAs and ischemic stroke subtypes may differ
with the most beneficial results observed in subjects with strokes of atherosclerotic etiology.
4. LA and Ischemic Stroke
Studies of the association between dietary intake of LA and the rate of ischemic stroke are sparse
(Table 6). In analyses based on data from the Swedish Mammography Cohort, no association was
observed between intake of LA+AA and the rate of total ischemic stroke [28]. Also, no clear association
was observed between LA+AA intake and the rate of total ischemic stroke in another Swedish
cohort [45]. However, the intake of LA and AA was not analysed separately and the macronutrient(s) to
be replaced for n-6 PUFAs was not specified in these studies. In contrast to n-3 PUFAs, LA constitute a
significant proportion of total energy intake and a higher intake of LA must necessarily be accompanied
by a lower intake of other macronutrients in an isocaloric setting. In a follow-up study using statistical
substitution models we therefore investigated the risk of total ischemic stroke and ischemic stroke
subtypes with a 5% higher intake of LA and a concomitant lower intake from saturated fatty acids
(SFAs), monounsaturated fatty acids (MUFAs) or glycemic carbohydrates using data from the DCH
cohort [36]. This study suggested that replacing MUFAs or glycemic carbohydrates with LA might
be associated with a lower risk of total ischemic stroke although not statistically significantly [36].
Further, in analyses of ischemic stroke subtypes, replacement of SFA with LA indicated a lower rate of
ischemic stroke due to large artery atherosclerosis and replacement of glycemic carbohydrates with
LA indicated a lower rate of ischemic stroke due to small-vessel occlusions, although the observed
associations were not statistically significant [36] (Table 2). A statistically significant lower rate of
ischemic stroke due to small-vessel occlusions was observed when LA replaced MUFAs [36] (Table 2).
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Table 6. Characteristics of observational follow-up studies investigating intake of linoleic acid (LA) and total ischemic stroke.
Author and
Study
Study Population
and Country Sex
No. of
Participants
Baseline
Age (yrs)
Exposure
Assessment Intake (g/d)
No. of
Cases
Follow-up
(yrs)
Hazard Ratios
(95% CI) Variables Controlled for
Larsson et al.
2012 [28]
The Swedish
Mammography
Cohort, Sweden
W 34,670 49–83 FFQ
LA+AA
Q1: 4.7
Q3: 6.0
Q5: 8.0
1310 10.4
Q2: 0.98 (0.84; 1.16)
Q3: 0.96 (0.81; 1.14)
Q4: 1.02 (0.85; 1.21)
Q5: 0.96 (0.80; 1.15)
Age; smoking status and pack-years of
smoking; education; BMI; physical
activity; hypertension; diabetes; aspirin;
family history of MI; intakes of alcohol,
protein, fiber and cholesterol.
Wallstrøm et
al. 2012 [45]
The Malmö Diet
and Cancer cohort,
Sweden
M & W M: 8083W: 12,402 44–73
Combined
FFQ, 7-day
diet history
and 1 h diet
interview
LA+AA:
Q1: 3.5% 1
Q3: 5.0% 1
Q5: 7.1% 1
W:
Q1: 3.3% 1
Q3: 4.7% 1
Q5: 6.7% 1
M: 397W:
346 13.5
M:
Q2: 1.12 (0.82; 1.52)
Q3: 1.02 (0.74; 1.39)
Q4: 1.10 (0.80; 1.50)
Q5: 1.16 (0.84; 1.58)
W:
Q2: 0.99 (0.72; 1.36)
Q3: 0.86 (0.62; 1.19)
Q4: 1.02 (0.73; 1.41)
Q5: 0.81 (0.57; 1.14)
Age; diet assessment method version; total
energy intake; season; BMI; smoking;
education; alcohol; systolic blood pressure,
anti-hypertensive treatment;
anti-hyperlipidemic treatment; leisure
time physical activity; dietary fiber.
Venø et al.
2017 [36]
The DCH cohort;
Denmark M+W 55,338 50–65 FFQ Median 10.7 1879 13.5
LA for SFA:
0.98 (0.83; 1.16)
LA for MUFA
0.80 (0.63; 1.02)
LA for glycemic
carbohydrates:
0.92 (0.78; 1.09)
Age; sex; total energy intake; education
status; physical activity; waist
circumference adjusted for BMI; alcohol;
alcohol abstain; smoking.
Abbreviations: M, men; W, Women; FFQ, Food Frequency Questionnaire; AA, Arachidonic acid; Q, Quintile; CI, Confidence interval; BMI, Body mass index; MI, Myocardial infarction; SFA,
Saturated fatty acids; MUFA, Monounsaturated fatty acids; DCH, Diet Cancer and Health. The presented measures of association was selected for models that included adjustment for
lifestyle factors without including dietary covariates whenever possible. The lowest group of exposure was used as reference unless otherwise indicated. 1 Percentage of total energy intake.
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Several prospective biomarker studies have supported that circulating or adipose tissue content
of LA may be associated with a lower risk of ischemic stroke although results have not been
consistent [23,31,32,37–40,49] (Table 7). A previous study by Iso et al. suggested a lower odds of total
ischemic stroke and lacunar infarctions per 1 SD increase in LA content in serum [31]. Also, in analyses
based on data from the ARIC Study, a statistically significant inverse association between LA content in
plasma cholesterol esters and the rate of total ischemic stroke and indications of an inverse association
was observed between LA content in plasma phospholipids and the rate of total ischemic stroke [39].
Also, several other studies have indicated a lower risk of total ischemic stroke with the content of
LA in serum, plasma phospholipids and cholesterol esters, but these findings were not statistically
significant and not entirely consistent [32,38,40,49]. However, a large case-cohort study based on data
from the DCH study found a dose-dependent inverse association between adipose tissue content
of LA and the rate of total ischemic stroke [37]. In analyses of ischemic stroke subtypes, adipose
tissue content of LA was inversely associated with the rate of ischemic stroke due to large artery
atherosclerosis and indications of lower rates of ischemic stroke due to small-vessel occlusions was
observed, whereas no clear association was found between LA in adipose and the rate of ischemic stroke
due to cardioembolism [37]. Recently, a harmonized individual-level analysis based on prospective
data from the Fatty Acid and Outcome Research Consortium (FORCE) found an overall lower rate of
total ischemic stroke with higher levels of LA in blood compartments and adipose tissue in analyses
including 3705 incident ischemic stroke cases [23].
Nutrients 2019, 11, 1467 16 of 20
Table 7. Characteristics of observational follow-up and nested case-control studies investigating biomarkers of linoleic acid (LA) and total ischemic stroke.
Author and
Study
Study Population,
Design and Country Sex
No. of Partici-pants
and Cases
Baseline Age
(yrs) Biomarker
Concentrations
(%)
Follow-up
(yrs)
Measure of
Association (95% CI) Variables Controlled for
Iso et al. 2002
[31]
A Japanese
cardiovascular risk
survey population;
Nested case-control;
Japan
M+W 122 cases & 366controls 40–85 LA in serum
Cases: 26.1%
Controls: 27.9% Not reported
OR 0.66 (0.49; 0.88) per
1 SD increase in LA
Age; sex; community; year of serum
storage; fasting status; BMI; cigarette
smoking status; alcohol; hypertension;
serum cholesterol levels, triglyceride
and glucose levels.
Yaemsiri et al.
2013 [32]
The WHI-OS cohort;
Nested case-control;
United status
W 964 cases &964controls 50–79 LA in serum
Cases: 26.7%
Controls: 27.1% Not reported
OR: 0.92 (0.79; 1.08) for
1 SD increase in LA 2
Age; race; time of follow-up; BMI;
smoking status; diabetes; aspirin.
Yamagishi et
al. 2013 [39]
The Minneapolis field
center of the ARIC
cohort; Follow-up;
United States
M+W 3870 subjectsincluding 168 cases 45–65
LA in PL and
CE
(separately)
CE:
Q1: 21.5–51.3%
Q4: 57.4–68.2%
PL:
Q1: 9.0–20.3%
Q4: 23.7–32.4%
19.9
HR for Q4 vs. Q1:
CE: 0.64 (0.43; 0.97)
PL: 0.69 (0.45; 1.05)
Age and sex. The authors stated that
the point estimated did not materially
change after additional adjustment for
smoking status; cigarette-years and
alcohol intake.
De Goede et
al. 2013 [38]
The MORGEN Study
cohort; Nested-case
control; The
Netherlands
M+W 93 cases & 93 controls 20–65 LA in CE Cases: 54.2%Controls: 55.4% 10.5
OR: 0.81 (0.54; 1.24) for
1 SD increase in LA
Age; gender; enrollment date;
smoking; BMI; alcohol; high
educational level; diabetes;
hypertension; hypercholesterolemia.
Wu et al. 2014
[49]
The CHS cohort,
Follow-up, United
States
M+W 2792 subjectsincluding 362 cases ≥65 LA in PL
Q1: 16.6%
Q3: 19.7%
Q5: 22.9%
12.3 1
Q2: 1.00 (0.71; 1.40)
Q3: 0.90 (0.64; 1.27)
Q4: 0.88 (0.62; 1.26)
Q5: 0.88 (0.61; 1.27)
Age; sex; race; enrollment site;
education; smoking status; diabetes;
atrial fibrillation; hypertension;
leisure-time physical activity; BMI;
waist circumference; alcohol; plasma
LC n-3 PUFAs.
Daneshmand
et al. 2016 [40]
The KIHD cohort;
Follow-up; Finland M
1828 subjects
including 153 cases 42–60 LA in serum
Q1: <23.7%
Q4: >29.5% 21.2
Q2: 0.72 (0.46; 1.14)
Q3: 0.87 (0.55; 1.37)
Q4: 1.07 (0.68; 1.67)
Age; examination year; BMI; smoking
status; physical activity; alcohol.
Venø et al.
2018 [37]
The DCH cohort,
Case-cohort, Denmark M+W
55,338 subjects
including 1755 cases 50–65
LA in adipose
tissue
Q1: <9.6%
Q4: >11.7% 13.5
Q2: 0.92 (0.77; 1.09)
Q3: 0.85 (0.71; 1.02)
Q4: 0.78 (0.65; 0.93)
Age; sex; alcohol; alcohol abstain;
waist circumference adjusted for BMI;
education status; smoking; physical
activity.
Marklund et
al. 2019 [23]
FORCE Consortium;
Individual pooled
analysis of cohort
studies Multinational
M+W
The FORCE
Consortium
population including
3705 cases
49–77 LA in PL, TP;CE, & AT
PL: 6.9%
TP: 11.4%
CE: 11.9%
RBC: 4.9%
AT: 6.2%
2.5–31.9
HR per IQR:
PL: 0.95 (0.82; 1.10)
TP: 0.84 (0.66; 1.06)
CE: 0.67 (0.51; 0.88)
AT: 0.87 (0.65; 1.15)
Overall: 0.88 (0.79; 0.98)
Age; sex; race; field center; BMI;
education; smoking; physical activity;
alcohol; diabetes; treated
hypertension; treated
hypercholesterolemia; aspirin; levels
of ALA, EPA and trans isomers of oleic
acid and trans isomers of linoleic acid.
Abbreviations: M, men; W, Women; OR, odds ratio; SD, standard deviation; BMI, Body mass index; WHI-OS, Women’s Health Initiative Observational Follow-up Study; ARIC,
Atherosclerosis Risk in Communities; CE, Cholesterol ester; PL, Phospholipids; HR, Hazard ratio; CI, Confidence interval; Q, Quintile; MORGEN, Monitoring Project on Risk Factors for
Chronic Diseases; CHS, Cardiovascular Health Study; LC n-3, Long-chain n-3 polyunsaturated fatty acids; KIHD, Kuopio, Ischaemic Heart Disease Risk Factor Study; DCH, Diet, Cancer
and Health; FORCE, Fatty Acid and Outcomes Research Consortium; TP, Total plasma; AT, Adipose tissue; ALA, alpha-linolenic acid; EPA, Eicosapentanoic acid. The presented measures
of association was selected for models that included adjustment for lifestyle factors without including dietary covariates whenever possible. The lowest group of exposure was used as
reference unless otherwise indicated. 1 Follow-up time was calculated as person-years of follow-up divided by the total number of participants; 2 99% confidence interval.
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In summary, limited evidence regarding LA intake and ischemic stroke exist, but LA intake
might be associated with a lower risk of total ischemic stroke although the association may depend on
macronutrient used to replace LA and the ischemic stroke subtype in question. Several biomarker
studies have supported that a high content of LA in blood components or adipose tissue may be
associated with a lower risk of total ischemic stroke.
5. Discussion
Several prospective follow-up studies have suggested that LC n-3 PUFAs perhaps in particular
EPA and DHA may be associated with a lower risk of total ischemic stroke although results have not
been consistent. A few studies have suggested that the associations between individual LC n-3 PUFAs
may differ amongst subtypes of ischemic stroke with the most beneficial findings observed in ischemic
strokes of presumed atherosclerotic origin. Regarding the role of ALA for development of ischemic
strokes, most prospective studies have not supported that ALA may be appreciably associated with a
lower risk of ischemic stroke. The associations between LA and ischemic stroke have been less studied
than the role of n-3 PUFAs, but some biomarker studies have supported that LA might be associated
with a lower risk of ischemic stroke. Limited evidence exist regarding LA intake and ischemic stroke,
but the association may depend on the macronutrient used to replace LA.
Biomarkers of PUFA exposure may represent useful complementary measures of exposure to
investigate the associations with chronic diseases such as ischemic stroke [50]. Dietary studies using
estimated PUFA intakes as exposure are limited by measurement error, which may result in loss of
statistical power and attenuation of associations toward null. In contrast, the content of PUFAs in blood
components or adipose tissue can be assessed more precise and are considered objective biomarkers of
exposure [50,51]. Long-term measures of exposure is likely to be of greater etiological relevance in
the development of ischemic stroke compared to short-term measures of exposure. Adipose tissue is
considered the gold standard due to a slow turnover time possibly reflecting intake of PUFAs during
the previous 1–2 years, whereas shorter-term biomarkers such as PUFA content in blood components
may represent the exposure up to few months. However, the content of PUFAs in blood components
or adipose tissue reflects both intake and metabolism [50]. Also, direct comparison of measures of
associations obtained in previous biomarker of PUFAs from different population should be done with
caution because differences in PUFA content in human tissue may be largely influenced by differences
in the underlying dietary pattern [50,51].
Finally, ischemic stroke is a heterogeneous condition and it is likely that the biological effects
of individual LC n-3 PUFAs and LA may differ across subtypes of ischemic stroke of different
etiology. Ischemic stroke due to large artery atherosclerosis is considered to be of atherosclerotic origin,
whereas ischemic stroke due to small-vessel occlusion may develop as a result of atherosclerosis or
lipohyalinosis affecting the smaller penetrating arteries in the brain [52,53]. In contrast, ischemic
cardio-embolic strokes are mainly caused by emboli arising from the heart due to arrhythmias,
particularly atrial fibrillation or flutter. Furthermore, ischemic stroke may in rare cases develop as a
result of nonatherosclerotic vasculopathies or prothrombotic disorders. Thus, these rather distinct
potential causes of ischemic stroke underline that separate analyses of ischemic stroke subtypes may
contribute with a better understanding of the underlying biology of exposure to PUFAs. Recent results
based on data from the DCH cohort [35] and the pooled analyses by Saber et al. [34] indicated that the
associations between individual LC n-3 PUFAs and ischemic stroke subtypes may differ. Interestingly,
results from the DCH cohort indicated stronger associations for EPA and LA on ischemic stroke due
to large artery atherosclerosis than for ischemic stroke due to small-vessel occlusion. This might
indicate that potential anti-atherosclerotic properties of marine n-3 PUFAs may be of importance.
Anti-atherosclerotic properties of LC n-3 PUFAs may include lowering of triglycerides and perhaps
also of atherogenic small-dense LDL particles, a reduction in inflammation and blood pressure, while
LA might inhibit the atherosclerotic process by lowering of LDL-cholesterol and blood pressure. EPA
seemed to be stronger associated ischemic stroke due to large artery atherosclerosis than DHA in
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the DCH cohort, but whether these differences can be attributed to different biological effects remain
unclear, but is not unlikely as many data support that a major effect of DHA on heart disease may be
an antiarrhythmic effect.
In addition, the associations may depend on the macronutrients used to replace PUFAs and
such substitution aspects together—with focus on dietary patterns—represent interesting areas for
future research.
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